Dupilumab for nephrotic syndrome in children
Treatments studied
Part of Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests if dupilumab can help children with nephrotic syndrome who still have relapses despite standard treatments. It aims to find a better way to control the disease and reduce steroid side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 6 and 18 years old and have nephrotic syndrome that started between ages 1 and 18.
- Your nephrotic syndrome is either steroid-dependent or frequently relapsing, even with maintenance therapy.
- You have been on oral prednisolone, with or without mycophenolate or levamisole, for at least 6 months and still have poor control or side effects.
- You have had a relapse or partial relapse within the last year that needed more steroids, but you are now in complete remission.
- You are able to check your urine for protein daily and follow the study instructions.
- You have not used rituximab or other B-cell depleting drugs in the past year and do not have certain eye, kidney, or infection problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether rituximab alone can help children with new-onset idiopathic nephrotic syndrome. It compares the treatment approach in order to see if it improves kidney recovery and reduces disease activity.
This trial tests whether rituximab works as well as mycophenolate in children whose nephrotic syndrome (kidney condition) comes back when steroid medicines are reduced. It aims to find the safest and most effective option during a relapse.
This trial tests if a hormone called ACTH can help children with nephrotic syndrome who have frequent relapses or need steroids to stay in remission. It aims to find a treatment that may reduce the need for steroids and prevent relapses.
This study tests an injection (SG301) that targets a protein called CD38 to help children whose nephrotic syndrome keeps coming back or depends on steroids. The goal is to see if the treatment can reduce relapses and the need for steroids.
This trial tests a new drug called telitacicept to help children whose nephrotic syndrome keeps coming back often or who need steroids to stay in remission. The goal is to see if it can keep urine protein levels low and reduce relapses.
This study is looking for children newly diagnosed with idiopathic nephrotic syndrome (a kidney condition that causes swelling and protein in the urine) who have not yet been treated. Researchers will study their blood and genes to find better ways to predict how the disease will progress and which treatments might work best.
Hear when a new Nephrotic Syndrome in Children trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.